PE20191819A1 - Analogos de deutetrabenazina, su preparacion y uso - Google Patents
Analogos de deutetrabenazina, su preparacion y usoInfo
- Publication number
- PE20191819A1 PE20191819A1 PE2019001871A PE2019001871A PE20191819A1 PE 20191819 A1 PE20191819 A1 PE 20191819A1 PE 2019001871 A PE2019001871 A PE 2019001871A PE 2019001871 A PE2019001871 A PE 2019001871A PE 20191819 A1 PE20191819 A1 PE 20191819A1
- Authority
- PE
- Peru
- Prior art keywords
- deutetrabenazine
- analogs
- preparation
- compound
- methods
- Prior art date
Links
- MKJIEFSOBYUXJB-VFJJUKLQSA-N (3r,11br)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical class C1CN2C[C@@H](CC(C)C)C(=O)C[C@@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-VFJJUKLQSA-N 0.000 title abstract 5
- 229950005031 deutetrabenazine Drugs 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 abstract 2
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 2
- 229940088679 drug related substance Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Machine Translation (AREA)
- Pens And Brushes (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471484P | 2017-03-15 | 2017-03-15 | |
| PCT/US2018/022562 WO2018170214A1 (en) | 2017-03-15 | 2018-03-15 | Analogs of deutetrabenazine, their preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191819A1 true PE20191819A1 (es) | 2019-12-27 |
Family
ID=61873991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001871A PE20191819A1 (es) | 2017-03-15 | 2018-03-15 | Analogos de deutetrabenazina, su preparacion y uso |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11813232B2 (enExample) |
| EP (1) | EP3596077A1 (enExample) |
| JP (3) | JP7608050B2 (enExample) |
| KR (2) | KR20200003791A (enExample) |
| CN (1) | CN110709398A (enExample) |
| AR (1) | AR111182A1 (enExample) |
| AU (2) | AU2018236336B2 (enExample) |
| BR (1) | BR112019018966A2 (enExample) |
| CA (1) | CA3056612A1 (enExample) |
| CL (1) | CL2019002629A1 (enExample) |
| CO (1) | CO2019011271A2 (enExample) |
| EA (1) | EA201992168A1 (enExample) |
| IL (1) | IL269132A (enExample) |
| MX (1) | MX2019010913A (enExample) |
| PE (1) | PE20191819A1 (enExample) |
| SG (1) | SG11201908477QA (enExample) |
| TW (1) | TWI772382B (enExample) |
| UA (1) | UA127052C2 (enExample) |
| WO (1) | WO2018170214A1 (enExample) |
| ZA (1) | ZA201906326B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11813232B2 (en) | 2017-03-15 | 2023-11-14 | Auspex Pharmaceuticals, Inc. | Analogs of deutetrabenazine, their preparation and use |
| WO2020123900A1 (en) | 2018-12-13 | 2020-06-18 | Auspex Pharmaceuticals, Inc. | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
| WO2020165807A1 (en) * | 2019-02-14 | 2020-08-20 | Dr. Reddy's Laboratories Limited | Solid forms of deutetrabenazine and process for the preparation thereof |
| US12599598B2 (en) | 2020-06-10 | 2026-04-14 | Auspex Pharmaceuticals Llc | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| EP4153136B1 (en) * | 2020-06-10 | 2024-01-10 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| CA2736409C (en) * | 2008-09-18 | 2017-07-11 | Auspex Pharmaceutical, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2801061A1 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| US9550780B2 (en) * | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CN105873589B (zh) | 2013-12-03 | 2019-11-01 | 奥斯拜客斯制药有限公司 | 制造苯并喹啉化合物的方法 |
| CN114767672A (zh) | 2015-03-06 | 2022-07-22 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
| US11813232B2 (en) | 2017-03-15 | 2023-11-14 | Auspex Pharmaceuticals, Inc. | Analogs of deutetrabenazine, their preparation and use |
-
2018
- 2018-03-15 US US15/922,329 patent/US11813232B2/en active Active
- 2018-03-15 UA UAA201910309A patent/UA127052C2/uk unknown
- 2018-03-15 KR KR1020197030354A patent/KR20200003791A/ko not_active Ceased
- 2018-03-15 SG SG11201908477Q patent/SG11201908477QA/en unknown
- 2018-03-15 MX MX2019010913A patent/MX2019010913A/es unknown
- 2018-03-15 PE PE2019001871A patent/PE20191819A1/es unknown
- 2018-03-15 KR KR1020227043234A patent/KR20230003308A/ko not_active Ceased
- 2018-03-15 TW TW107108832A patent/TWI772382B/zh active
- 2018-03-15 EP EP18715393.7A patent/EP3596077A1/en active Pending
- 2018-03-15 BR BR112019018966-1A patent/BR112019018966A2/pt not_active Application Discontinuation
- 2018-03-15 CN CN201880018609.8A patent/CN110709398A/zh active Pending
- 2018-03-15 EA EA201992168A patent/EA201992168A1/ru unknown
- 2018-03-15 CA CA3056612A patent/CA3056612A1/en active Pending
- 2018-03-15 AR ARP180100611A patent/AR111182A1/es not_active Application Discontinuation
- 2018-03-15 JP JP2019550774A patent/JP7608050B2/ja active Active
- 2018-03-15 WO PCT/US2018/022562 patent/WO2018170214A1/en not_active Ceased
- 2018-03-15 AU AU2018236336A patent/AU2018236336B2/en active Active
-
2019
- 2019-09-04 IL IL26913219A patent/IL269132A/en unknown
- 2019-09-13 CL CL2019002629A patent/CL2019002629A1/es unknown
- 2019-09-25 ZA ZA2019/06326A patent/ZA201906326B/en unknown
- 2019-09-25 US US16/582,362 patent/US11179386B2/en active Active
- 2019-10-10 CO CONC2019/0011271A patent/CO2019011271A2/es unknown
-
2021
- 2021-10-21 US US17/507,037 patent/US12502385B2/en active Active
- 2021-11-30 US US17/537,663 patent/US20220088006A1/en not_active Abandoned
-
2022
- 2022-05-18 AU AU2022203369A patent/AU2022203369B2/en active Active
- 2022-11-04 JP JP2022177578A patent/JP2023010754A/ja active Pending
-
2024
- 2024-01-30 JP JP2024011974A patent/JP7631572B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| UY38602A (es) | Compuestos tricíclicos condensados | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| CL2024000714A1 (es) | Compuestos espirocíclicos | |
| UY33491A (es) | ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?. | |
| ECSP22032851A (es) | Inhibidores del fxia y m?todo de preparaci?n de los mismos y uso farmac?utico de los mismos | |
| DOP2010000387A (es) | Compuestos pirazolicos 436 | |
| AR049578A1 (es) | Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas | |
| NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
| UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| CO2023014204A2 (es) | Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7) | |
| BR112017027688A2 (pt) | Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados | |
| UY35535A (es) | ?Derivados de fenil sulfonamidas?. | |
| CO2024000054A2 (es) | Forma cristalina de tolebrutinib y método de preparación y su uso | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| CR20190379A (es) | Moduladores del receptor de estrógeno | |
| ECSP22049160A (es) | Derivados de bencimidazol | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| AR057162A1 (es) | Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac) | |
| AR111182A1 (es) | Composición farmacéutica de análogos de deutetrabenazina, su preparación y uso | |
| UY35536A (es) | ?derivados de sulfonamida?. | |
| UY28979A1 (es) | Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3 | |
| PE20210550A1 (es) | Compuestos de 4-metildihidropirimidinona y su uso farmaceutico |